Bacteriophage Therapy: An Alternative to Antibiotics—An Experimental Study in Mice

Abstract

The present study was planned to evaluate the efficacy of Pseudomonas aeruginosa specific phages in immunocompromised septicemia animal model as an alternative to antibiotics. Five different sets of experiments were performed: prophylactic administration of phage cocktail (3 lytic and unique) before and simultaneous with bacterial challenge; and therapeutic, that is, administration of phage cocktail 6, 12, and 24 hours after the bacterial challenge. No mortality was observed when simultaneous and late administration of phages was done with respect to the bacterial challenge. Contrary to this, administration of phage cocktail 100 µL (10¹² PFU/mL) of volume after 6 hours of the infection resulted in a mortality rate of 60%. However, no mortality could be observed with reduced dose of cocktail, that is, 10⁸, 10⁹, and 10¹⁰ PFU administered 6 hours after bacterial challenge. Phage therapy in acute infections initiated with very small dosage under strict supervision may give better results. However, further studies to determine the quantity and frequency of dosage of phage cocktail for septicemia of various durations is strongly indicated.

Keywords

Pseudomonas aeruginosa - bacteriophage cocktail - multidrug resistant - mouse model

• References

• 1 Trautmann M, Lepper PM, Haller M. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am J Infect Control 2005; 33 (05) (Suppl. 01) S41-S49
• 2 Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2000; 2 (09) 1051-1060
• 3 Schroeder TH, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J Immunol 2001; 166 (12) 7410-7418
• 4 Bragonzi A, Paroni M, Nonis A. et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 2009; 180 (02) 138-145
• 5 Breidenstein EBM, de la Fuente-Núñez C, Hancock REW. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011; 19 (08) 419-426
• 6 Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2: 65
• 7 Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2000; 44 (03) 640-646
• 8 Priebe GP, Goldberg JB. Vaccines for. Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines 2014; 13 (04) 507-519
• 9 Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 2015; 89 (15) 7449-7456
• 10 Debarbieux L, Leduc D, Maura D. et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010; 201 (07) 1096-1104
• 11 Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J Med Microbiol 2011; 60 (Pt 2) 205-210
• 12 Khawaldeh A, Morales S, Dillon B. et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J Med Microbiol 2011; 60 (Pt 11) 1697-1700
• 13 Watanabe R, Matsumoto T, Sano G. et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 2007; 51 (02) 446-452
• 14 Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J Infect Dev Ctries 2014; 8 (02) 129-136
• 15 Rossitto M, Fiscarelli EV, Rosati P. Challenges and promises for planning future clinical research into bacteriophage therapy against Pseudomonas aeruginosa in cystic fibrosis. An argumentative review. Front Microbiol 2018; 9: 775
• 16 McVay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 2007; 51 (06) 1934-1938
• 17 Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa . Evol Med Public Health 2018; 2018 (01) 60-66
• 18 Ellis EL, Delbrück M. The growth of bacteriophages. J Gen Physiol 1939; 22 (03) 365-384
• 19 Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed.. New York, NY: Cold Spring Harbor Laboratory Press, Cold Spring Habor;
• 20 Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991; 19 (24) 6823-6831
• 21 Romesburg HC. Cluster Analysis for Researchers. Morrisville, NC: Lulu Press; 2004
• 22 Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A 2002; 99 (03) 1503-1508
• 23 Horii T, Ichiyama S, Ohta M, Kobayashi M. Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa . J Med Microbiol 1999; 48 (03) 309-315
• 24 Prins JM. Antibiotic induced release of endotoxin clinical data and human studies. J Endotoxin Res 1996; 3 (03) 269-273